Pioneering the future: CRISPR-Cas9 gene therapy for hereditary hemorrhagic telangiectasia.
European journal of internal medicine, 127: 140-141 PMID 38879351 DOI 10.1016/j.ejim.2024.06.012
Abstract
This article has no abstract in PubMed.
Your browser does not allow saving data (e.g. private mode): bookmarks will be lost when the tab closes.